Contact Us
Drug Search Results
More Filters [+]

Solanezumab

Alternative Names: solanezumab, ly-2062430, ly2062430, ly 2062430
Latest Update: 2024-07-02
Latest Update Note: Clinical Trial Update

Product Description

Eli Lilly is developing Solanezumab as a treatment for Alzheimer's disease. (Sourced from: https://investor.lilly.com/news-releases/news-release-details/lilly-provides-update-a4-study-solanezumab-preclinical)

Mechanisms of Action: AB Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Solanezumab

Countries in Clinic: Australia, Canada, Japan, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Alzheimer Disease|Cognition Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
jRCT2080223287

P3

Completed

Alzheimer Disease

2023-12-31

A4

P3

Completed

Cognition Disorders

2022-12-27

JapicCTI-163169

P1

Active

Alzheimer Disease

None

JapicCTI-163429

P3

Active

Unknown

None

Recent News Events

Date

Type

Title

05/13/2024

PubMed

 Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.

05/07/2024

PubMed

 Passive immunotherapy for Alzheimer's disease: challenges & future directions.

01/01/2024

PubMed

 Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.

09/28/2023

News Article

 Alzheimer Drugs Market by Product Type, End-User, Application, Region Global Forecast to 2032

09/27/2023

News Article

 Alzheimers Disease (AD) Diagnostics and Therapeutics Market 2023 Report Revealing the Latest Trends and Outlook for Advancements by 2030

09/25/2023

News Article

 Alzheimers Disease (AD) Diagnostics and Therapeutics Market 2023 Production, Industry Statistics, Size, Growth, Overview, and Forecast Report till 2030

09/01/2023

News Article

 Alzheimers Disease (AD) Diagnostics and Therapeutics Market Trade Research Report 2023-2030

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions